Home / BCLI : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BCLI make money? Does BCLI have pricing power? What's the Earnings Whisper? Will BCLI profit more as the business scales? What is BCLI's management track record? Is BCLI's current price justified?

Brainstorm Cell Therapeutics Inc.

$1.08 +$0.47 (+77.05%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$1.03

Day Range

$1.02$1.08

Year Range

$0.46$1.69

Market Cap

11.92M

AVG Volume

23.77K

Trailing/Forward PE

-1.14/-

PEG ratio

-0.09

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

Other OTC

Revenue (USD)

BCLI Revenue (USD) by year
Period	Revenue (USD)
2025	0
2024	0
2023	343K
2022	0
2021	0
2020	0
2019	1.04M
2018	0
2017	0
2016	0

Net Income (USD)

BCLI Net Income (USD) by year
Period	Net Income (USD)
2025	-10.31M
2024	-11.62M
2023	-17.19M
2022	-24.28M
2021	-24.46M
2020	-31.81M
2019	-23.25M
2018	-13.95M
2017	-4.95M
2016	-4.98M

Operating Income (USD)

BCLI Operating Income (USD) by year
Period	Operating Income (USD)
2025	-9.95M
2024	-11.69M
2023	-21.44M
2022	-24.82M
2021	-24.54M
2020	-31.68M
2019	-23M
2018	-14.06M
2017	-5M
2016	-5.08M

EBITDA (USD)

BCLI EBITDA (USD) by year
Period	EBITDA (USD)
2025	-9.75M
2024	-11.45M
2023	-21.95M
2022	-24.54M
2021	-24.28M
2020	-31.46M
2019	-22.84M
2018	-13.95M
2017	-4.91M
2016	-5.01M

Cash Flows (USD)

BCLI Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-6.97M
2024	-9.09M
2023	-20.48M
2022	-19.35M
2021	-26.59M
2020	-35.57M
2019	-11.72M
2018	-12.76M
2017	-2.54M
2016	-5.96M

EPS (USD)

BCLI EPS (USD) by year
Period	EPS (USD)
2025	-1.2
2024	-2.36
2023	-6.13
2022	-8.09
2021	-7.82
2020	-10.98
2019	-11.07
2018	-6.71
2017	-4.34
2016	-3.63

Expenses (USD)

BCLI Expenses (USD) by year
Period	Expenses (USD)
2025	0
2024	11.63M
2023	21.46M
2022	24.85M
2021	24.87M
2020	32.06M
2019	23.47M
2018	14.43M
2017	5.18M
2016	5.19M

Cash & Debt (USD)

BCLI Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	29K
2024	187K
2023	1.3M
2022	2.98M
2021	22.09M
2020	41.94M
2019	569K
2018	7.06M
2017	7.76M
2016	9.99M

Debt ratios

BCLI Debt ratios by year
Period	Debt ratios
2025	-0
2024	-0.01
2023	0
2022	-0.01
2021	0.18
2020	0.47
2019	-0.04
2018	0.22

Margins

BCLI Margins by year
Period	Margins
2023	61.81%
2019	100%
2015	62.71%

Return on Capital

BCLI Return on Capital by year
Period	Return on Capital
2025	100.15%
2024	149.7%
2023	353.89%
2022	805.21%
2021	-126.45%
2020	-89.7%
2019	190.24%
2018	-278.07%
2017	-84.22%
2016	-50.31%

Shares Outstanding

BCLI Shares Outstanding by year
Period	Shares Outstanding
2025	9.27M
2024	5.71M
2023	3.36M
2022	2.44M
2021	2.42M
2020	2.13M
2019	1.51M
2018	1.38M
2017	1.26M
2016	1.25M

Book Value Per Share (USD)

BCLI Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	-1.11
2024	-1.36
2023	-1.44
2022	-1.24
2021	7.99
2020	16.66
2019	-8.07
2018	3.63
2017	4.67
2016	7.95

Total Assets (USD)

BCLI Total Assets (USD) by year
Period	Total Assets (USD)
2025	715K
2024	1.83M
2023	4.21M
2022	8.45M
2021	29.28M
2020	51.26M
2019	6.53M
2018	11.23M
2017	11.42M
2016	10.77M

Employee Count

BCLI Employee Count by year
Period	Employee Count
2025	20
2024	29
2023	29
2022	41
2021	43
2020	40
2019	32
2018	31
2017	24
2016	22

Free Cash Flow Yield

BCLI Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-34.04%
Sep 26	-35.01%
Aug 26	-32.83%
Aug 26	-37.52%
Aug 26	-37.14%
Aug 26	-76.68%
Jul 26	-67.1%
Jul 26	-62.91%
Jul 26	-67.39%
Jul 26	-55.92%
Jul 26	-41.94%
Jun 26	-64.94%
Jun 26	-69.86%
Jun 26	-80.51%
Jun 26	-80.67%
May 26	-80.52%
May 26	-88.8%
May 26	-87.52%
May 26	-108.34%
May 26	-114.46%
Apr 26	-97.73%
Apr 26	-89.36%
Apr 26	-81.53%
Apr 26	-83.61%
Mar 26	-73.68%
Mar 26	-78.48%
Mar 26	-88.21%
Mar 26	-93.18%
Feb 26	-94.58%
Feb 26	-108.46%
Feb 26	-124.83%
Feb 26	-114.07%
Jan 26	-105.02%
Jan 26	-110.27%
Jan 26	-112.14%
Jan 26	-122.52%
Jan 26	-108.46%
Dec 25	-98.75%
Dec 25	-118.14%
Dec 25	-118.14%
Dec 25	-110.27%
Nov 25	-103.38%
Nov 25	-103.38%
Nov 25	-108.46%
Nov 25	-164.14%
Oct 25	-169.19%
Oct 25	-154.89%
Oct 25	-169.19%
Oct 25	-159.38%
Oct 25	-152.74%
Sep 25	-154.89%
Sep 25	-157.1%
Sep 25	-157.1%
Sep 25	-154.89%
Aug 25	-144.7%
Aug 25	-169.19%
Aug 25	-174.56%
Aug 25	-208.27%
Aug 25	-180.3%
Jul 25	-167.77%
Jul 25	-143.81%
Jul 25	-100.66%
Jul 25	-104.14%
Jun 25	-113.96%
Jun 25	-99.01%
Jun 25	-109.82%
Jun 25	-99.01%
May 25	-107.86%
May 25	-111.85%
May 25	-91.51%
May 25	-135%
May 25	-126.43%
Apr 25	-163.39%
Apr 25	-181.85%
Apr 25	-208.95%
Apr 25	-138.52%
Mar 25	-179.31%
Mar 25	-151.33%
Mar 25	-134.2%
Mar 25	-133.36%
Feb 25	-133.36%
Feb 25	-123.34%
Feb 25	-114.72%
Feb 25	-124.78%
Jan 25	-117.24%
Jan 25	-97.43%
Jan 25	-112.9%
Jan 25	-105.63%
Jan 25	-95.69%
Dec 24	-87.09%
Dec 24	-93.59%
Dec 24	-147.16%
Dec 24	-134.2%
Nov 24	-122.63%
Nov 24	-170.7%
Nov 24	-176.35%
Nov 24	-253.77%
Nov 24	-163.72%
Oct 24	-155.37%
Oct 24	-135.35%

Price to Sales

BCLI Price to Sales by year
Period	Price to Sales
Mar 25	18.42
Mar 25	21.83
Mar 25	24.61
Mar 25	24.77
Feb 25	24.77
Feb 25	26.78
Feb 25	28.79
Feb 25	26.47
Jan 25	28.17
Jan 25	33.9
Jan 25	29.26
Jan 25	31.27
Jan 25	34.52
Dec 24	37.93
Dec 24	35.3
Dec 24	22.45
Dec 24	24.61
Nov 24	26.94
Nov 24	19.35
Nov 24	18.73
Nov 24	16.61
Nov 24	25.75
Oct 24	27.13
Oct 24	31.14
Oct 24	27.68
Oct 24	32.25
Sep 24	46.23
Sep 24	50.38
Sep 24	58.55
Sep 24	53.43
Aug 24	64.23
Aug 24	69.9
Aug 24	70.73
Aug 24	48.95
Aug 24	60.9
Jul 24	66.31
Jul 24	65.3
Jul 24	79.27
Jul 24	69.08
Jun 24	63.92
Jun 24	69.83
Jun 24	88.71
Jun 24	77.64
May 24	91.85
May 24	101.42
May 24	98.15
May 24	67.05
May 24	55.87
Apr 24	78.61
Apr 24	78.22
Apr 24	85.87
Apr 24	95.77
Oct 20	495.75
Oct 20	431.91
Sep 20	422.31
Sep 20	426.26
Sep 20	377.68
Sep 20	355.36
Aug 20	353.38
Aug 20	363.55
Aug 20	374.85
Aug 20	361.29
Jul 20	371.76
Jul 20	427.73
Jul 20	400.02
Jul 20	363.53
Jul 20	334.72
Jun 20	347.34
Jun 20	278.48
Jun 20	232.38
Jun 20	249.12
May 20	204.4
May 20	178.61
May 20	144.86
May 20	161.05
May 20	137.32
Apr 20	133.15
Apr 20	133.15
Apr 20	111.65
Apr 20	102
Mar 20	107.48
Mar 20	100.9
Mar 20	121.74
Mar 20	187.55
Feb 20	153.11
Feb 20	150.7
Feb 20	110.85
Feb 20	87.22
Jan 20	87.43
Jan 20	88.93
Jan 20	93.45
Jan 20	93.45
Jan 20	89.58
Dec 19	87.86
Dec 19	79.48
Dec 19	82.7
Dec 19	84.42
Nov 19	85.28
Nov 19	84.21
Nov 19	80.56

Price to Book

BCLI Price to Book by year
Period	Price to Book
Mar 23	40.75
Mar 23	42.33
Mar 23	42.59
Mar 23	54.95
Feb 23	59.68
Feb 23	61.79
Feb 23	76.77
Feb 23	70.99
Jan 23	39.96
Jan 23	39.96
Jan 23	38.39
Jan 23	41.28
Dec 22	43.12
Dec 22	44.7
Dec 22	50.48
Dec 22	36.02
Dec 22	43.64
Nov 22	44.7
Nov 22	40.23
Nov 22	7.06
Nov 22	15.66
Oct 22	15.84
Oct 22	14.78
Oct 22	16.17
Oct 22	17.47
Sep 22	20.54
Sep 22	19.52
Sep 22	19
Sep 22	17.66
Sep 22	15.57
Aug 22	18.12
Aug 22	17.56
Aug 22	8.8
Aug 22	7.47
Jul 22	6.44
Jul 22	6.61
Jul 22	6.64
Jul 22	7.07
Jul 22	6.92
Jun 22	6.84
Jun 22	7.27
Jun 22	7.44
Jun 22	7.6
May 22	7.5
May 22	7.27
May 22	5.1
May 22	5.71
Apr 22	5.63
Apr 22	5.8
Apr 22	5.91
Apr 22	6.76
Apr 22	6.21
Mar 22	4.92
Mar 22	4.92
Mar 22	4.52
Mar 22	4.31
Feb 22	4.43
Feb 22	4.65
Feb 22	4.66
Feb 22	4.53
Jan 22	4.47
Jan 22	4.52
Jan 22	5.17
Jan 22	5.45
Dec 21	5.83
Dec 21	5.42
Dec 21	5
Dec 21	4.98
Dec 21	4.85
Nov 21	5.45
Nov 21	4.24
Nov 21	3.57
Nov 21	3.63
Oct 21	3.48
Oct 21	3.71
Oct 21	3.71
Oct 21	3.76
Oct 21	3.92
Sep 21	4.06
Sep 21	4.25
Sep 21	3.95
Sep 21	4.16
Aug 21	4.25
Aug 21	3.95
Aug 21	4.43
Aug 21	4.77
Jul 21	3.98
Jul 21	3.35
Jul 21	3.3
Jul 21	3.44
Jul 21	3.69
Jun 21	3.96
Jun 21	3.86
Jun 21	3.91
Jun 21	3.58
May 21	3.54
May 21	3.47
May 21	3.34
May 21	3.13
Apr 21	3.43

No video analysis for this stock yet. Request one from our team.

News: BCLI

prnewswire.com · 24 Aug 2026

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.

prnewswire.com · 14 Aug 2026

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.

prnewswire.com · 28 Jul 2026

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team.